Heart failure in 2013: Continue what we are doing to treat HF, but do it better

Nature Reviews Cardiology

Volumn 11, Issue 2, 2014, Pages 69-70

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; DOPAMINE; IVABRADINE; NESIRITIDE; SILDENAFIL; SPIRONOLACTONE;

ACUTE HEART FAILURE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL (TOPIC); COLLAGEN SYNTHESIS; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DIURESIS; DIURETIC THERAPY; EARLY INTERVENTION; ECG ABNORMALITY; EVIDENCE BASED MEDICINE; EXERCISE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART RATE; HEMODYNAMICS; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; METABOLIC EQUIVALENT; MORBIDITY; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; QRS COMPLEX; QUALITY OF LIFE; REVIEW;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; WORLD HEALTH;

EID: 84893639875     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.212     Document Type: Review

References (10)

1. Cohn, J. N. Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition. Circulation 91, 2504-2507 (1995
2. Bristow, M. R. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350, 2140-2150 (2004
3. Chen, H. H. et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. JAMA http://dx.doi.org/10.1001/jama.2013.282190
4. Ruschitzka, F. et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N. Engl. J. Med. 369, 1395-1405 (2013
5. Redfield, M. M. et al. Effect of phosphodiesterase 5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 309, 1268-1277 (2013
6. Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 376, 875-885 (2010
7. Kosmala, W. et al. Effect of If channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: A randomized trial. J. Am. Coll. Cardiol. 62, 1330-1338 (2013
8. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999
9. Edelmann, F. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo DHF randomized controlled trial. JAMA 309, 781-791 (2013
10. Pfeffer, M. A. Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Presented at the American Heart Association Scientific Sessions 2013